Chardan Capital Brokers Increase Earnings Estimates for MCRB

Seres Therapeutics, Inc. (NASDAQ:MCRB) – Equities researchers at Chardan Capital lifted their FY2025 earnings estimates for Seres Therapeutics in a research report issued on Monday, March 24th. Chardan Capital analyst K. Nakae now expects that the biotechnology company will post earnings of ($0.57) per share for the year, up from their prior estimate of ($0.73). Chardan Capital has a “Buy” rating and a $1.25 price objective on the stock. The consensus estimate for Seres Therapeutics’ current full-year earnings is ($0.38) per share.

A number of other equities analysts also recently issued reports on the company. The Goldman Sachs Group lowered their price target on Seres Therapeutics from $1.00 to $0.75 and set a “sell” rating on the stock in a research report on Friday, March 14th. StockNews.com upgraded Seres Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, March 6th. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $4.00.

Seres Therapeutics Stock Up 2.5 %

NASDAQ:MCRB opened at $0.73 on Thursday. Seres Therapeutics has a 52 week low of $0.54 and a 52 week high of $1.53. The stock’s 50-day moving average price is $0.78 and its 200-day moving average price is $0.83. The stock has a market capitalization of $127.28 million, a PE ratio of -3.17 and a beta of 2.19.

Institutional Investors Weigh In On Seres Therapeutics

Several large investors have recently bought and sold shares of MCRB. Virtu Financial LLC boosted its stake in shares of Seres Therapeutics by 44.8% in the third quarter. Virtu Financial LLC now owns 58,791 shares of the biotechnology company’s stock worth $56,000 after acquiring an additional 18,191 shares during the last quarter. Providence Wealth Advisors LLC lifted its stake in Seres Therapeutics by 29.2% in the 3rd quarter. Providence Wealth Advisors LLC now owns 98,500 shares of the biotechnology company’s stock worth $93,000 after purchasing an additional 22,250 shares in the last quarter. Avantax Advisory Services Inc. raised its holdings in shares of Seres Therapeutics by 170.9% during the 4th quarter. Avantax Advisory Services Inc. now owns 45,179 shares of the biotechnology company’s stock worth $38,000 after acquiring an additional 28,500 shares during the period. Jane Street Group LLC boosted its position in shares of Seres Therapeutics by 181.4% during the 4th quarter. Jane Street Group LLC now owns 58,736 shares of the biotechnology company’s stock valued at $49,000 after acquiring an additional 37,866 shares during the last quarter. Finally, State Street Corp boosted its position in shares of Seres Therapeutics by 12.9% during the 3rd quarter. State Street Corp now owns 383,248 shares of the biotechnology company’s stock valued at $363,000 after acquiring an additional 43,700 shares during the last quarter. 59.34% of the stock is currently owned by hedge funds and other institutional investors.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.